Can-Fite BioPharma Ltd (CANF) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Can-Fite BioPharma is launching a Phase 2 pilot study of its drug piclidenoson in patients with Lowe syndrome, a rare genetic kidney disease. The trial, officially titled “An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome,” aims to test if this pill can improve kidney function and provide early safety data that could support future development.
The treatment under review is piclidenoson, an oral small-molecule drug taken twice a day for six months. The goal is to boost how well the kidneys reabsorb key proteins and to see if the therapy can ease signs of Fanconi syndrome, a core problem in Lowe syndrome.
The study is interventional, with one open-label treatment group and no placebo arm. All enrolled patients will receive piclidenoson, and both doctors and families will know the treatment, which helps collect early real-world style data but limits direct comparison to standard care.
The trial has not yet started recruiting; the sponsor submitted it on February 8, 2026, with the latest update filed on February 15, 2026. Primary completion and full completion dates are not posted yet, which means investors should expect early readouts to be at least several quarters away once enrollment begins.
For investors, this update signals that Can-Fite is expanding its pipeline into ultra-rare renal disease, a space often supported by premium pricing and regulatory incentives. While near-term revenue impact is unlikely, early success could improve sentiment around CANF by adding a high-value orphan indication and positioning the company alongside niche rare-disease players rather than broader inflammation peers.
The Lowe syndrome study of piclidenoson is now formally registered and updated, and the trial remains in the start-up phase with further details available on the ClinicalTrials portal.
To learn more about CANF’s potential, visit the Can-Fite BioPharma Ltd drug pipeline page.